Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Fineline Cube May 6, 2026
Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Fineline Cube May 6, 2026
Company Deals Medical Device

Thermo Fisher Mulls $4B Diagnostic Business Sale Amid Healthcare Sector Turbulence

Fineline Cube Jun 16, 2025

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) is reported by the Financial...

Company Drug

Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial

Fineline Cube Jun 16, 2025

China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary...

Company Drug

Novo Nordisk Advances Amycretin for Weight Management in Phase III Trials

Fineline Cube Jun 16, 2025

Denmark-based pharmaceutical major Novo Nordisk (NYSE: NVO) announced plans to advance both subcutaneous and oral...

Company Drug

FDA OKs MSD’s Keytruda for Perioperative Head and Neck Cancer Treatment With PD-L1 Expression

Fineline Cube Jun 16, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food...

Company Drug

GSK Seeks EMA Approval to Expand RSV Vaccine Arexvy Use to Adults Aged 18+

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has announced that the European Medicines Agency (EMA)...

Company

UCB Announces Investment in U.S. Biologics Production Facility

Fineline Cube Jun 16, 2025

Belgium-based biopharmaceutical company UCB (EBR: UCB) announced plans to invest in a cutting-edge biologics production...

Company Deals

Gene Solutions Partners with Shenzhen USK Bio to Advance Precision Oncology in Southern China

Fineline Cube Jun 16, 2025

Vietnam-headquartered Gene Solutions announced a Memorandum of Understanding (MOU) with China’s Shenzhen USK Bioscience Co.,...

Company Deals

MRI and Astellas Alliance to Boost Japanese Drug Discovery Startups

Fineline Cube Jun 16, 2025

Japan-based Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (TYO: 4503) announced the signing...

Company Drug

MSD Wins NMPA Approval for Keytruda-Lenvima Combo in Hepatocellular Carcinoma

Fineline Cube Jun 16, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...

Company Deals

Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline

Fineline Cube Jun 16, 2025

Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460),...

Company Drug

Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients

Fineline Cube Jun 16, 2025

Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in OSA and Obesity

Fineline Cube Jun 16, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the dosing of the first participant in China...

Company Drug

Abbisko Therapeutics Launches Clinical Study of FGFR4 Inhibitor in Advanced Hepatocellular Carcinoma

Fineline Cube Jun 16, 2025

Shanghai-based Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced the dosing of the first patient in...

Company Deals

Dessight Biomedical Secures RMB 100M Series A Funding for Surgical Robot Development

Fineline Cube Jun 16, 2025

Hangzhou-based Dessight Biomedical, a provider of ultra-microsurgery precision solutions, has completed a Series A funding...

Company Drug

AstraZeneca Launches Truqap in China for PIK3CA/AKT1/PTEN-Altered Breast Cancer

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in...

Company Deals

CR Sanjiu Partners with HELP Therapeutics to Advance iPSC-based Heart Failure Therapy

Fineline Cube Jun 16, 2025

China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, announced a partnership with Nanjing-based HELP...

Company Deals Hospital

Raffles Medical Partners with CQMU First Hospital to Enhance Healthcare Services

Fineline Cube Jun 16, 2025

Singapore-based Raffles Medical Group, a leading integrated healthcare provider with a broad presence in Asia,...

Company Deals

AstraZeneca and CSPC Pharma Collaborate on Novel Oral Drug Discovery

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) and China’s CSPC Pharmaceutical Group Ltd (HKG: 1093)...

Company Deals

CF PharmTech Files for Hong Kong IPO to Expand Respiratory Disease Treatments

Fineline Cube Jun 16, 2025

China-based CF PharmTech, Inc., a specialist in inhalable drugs for respiratory diseases, has filed for...

Company Deals

Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development

Fineline Cube Jun 16, 2025

Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong...

Posts pagination

1 … 138 139 140 … 660

Recent updates

  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
  • Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion
  • Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Company

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.